Oculis’ (OCS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Oculis (NASDAQ:OCS) in a report issued on Monday,Benzinga reports. The firm currently has a $30.00 price target on the stock.

Oculis Stock Performance

Shares of Oculis stock opened at $18.70 on Monday. The business has a 50-day simple moving average of $16.38 and a 200-day simple moving average of $13.87. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. Oculis has a one year low of $10.50 and a one year high of $18.72. The company has a market cap of $757.42 million, a PE ratio of -9.69 and a beta of -0.33.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.